Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment

[Image: see text] While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Victoria C., Muller, Florian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315846/
https://www.ncbi.nlm.nih.gov/pubmed/32665809
http://dx.doi.org/10.1021/acsmedchemlett.0c00316
_version_ 1783550328077025280
author Yan, Victoria C.
Muller, Florian L.
author_facet Yan, Victoria C.
Muller, Florian L.
author_sort Yan, Victoria C.
collection PubMed
description [Image: see text] While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and in vivo efficacy in the veterinary setting, we contend that GS-441524 is superior to remdesivir for Covid-19 treatment.
format Online
Article
Text
id pubmed-7315846
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-73158462020-06-25 Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment Yan, Victoria C. Muller, Florian L. ACS Med Chem Lett [Image: see text] While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and in vivo efficacy in the veterinary setting, we contend that GS-441524 is superior to remdesivir for Covid-19 treatment. American Chemical Society 2020-06-23 /pmc/articles/PMC7315846/ /pubmed/32665809 http://dx.doi.org/10.1021/acsmedchemlett.0c00316 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Yan, Victoria C.
Muller, Florian L.
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
title Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
title_full Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
title_fullStr Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
title_full_unstemmed Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
title_short Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
title_sort advantages of the parent nucleoside gs-441524 over remdesivir for covid-19 treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315846/
https://www.ncbi.nlm.nih.gov/pubmed/32665809
http://dx.doi.org/10.1021/acsmedchemlett.0c00316
work_keys_str_mv AT yanvictoriac advantagesoftheparentnucleosidegs441524overremdesivirforcovid19treatment
AT mullerflorianl advantagesoftheparentnucleosidegs441524overremdesivirforcovid19treatment

Ejemplares similares